Evercore ISI Begins Coverage on Homology Medicines (FIXX)

Evercore ISI assumed coverage on shares of Homology Medicines (NASDAQ:FIXX) in a research note issued to investors on Monday morning. The brokerage issued an outperform rating and a $30.00 price target on the stock.

Separately, Cowen assumed coverage on Homology Medicines in a research note on Monday. They issued an outperform rating for the company.

NASDAQ FIXX opened at $20.64 on Monday. Homology Medicines has a 52 week low of $16.12 and a 52 week high of $24.40.

In other news, major shareholder Vida Ventures, Llc bought 375,000 shares of the stock in a transaction dated Monday, April 2nd. The stock was bought at an average cost of $16.00 per share, with a total value of $6,000,000.00. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider James E. Flynn bought 1,250,000 shares of the stock in a transaction dated Monday, April 2nd. The stock was purchased at an average cost of $16.00 per share, with a total value of $20,000,000.00. The disclosure for this purchase can be found here.

About Homology Medicines

There is no company description available for Homology Medicines Inc

Receive News & Ratings for Homology Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Homology Medicines and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply